Natco Pharma stock rose 18% today and 26% in a four-day rise.
Natco Pharma stock: To account for the beat, higher gRevlimid, and reduced tax, Nuvama has increased its FY24E and FY25 EPS projections for Natco Pharma by 21% and 12%, respectively; the objective is Rs 1,055. In Friday’s trading, Natco Pharma Ltd. shares increased 18%, bringing their four-day advance to 26%. The medicine maker’s consolidated earnings…